Correspondingly, an interesting study by Kurimchak et al. showed that BET inhibitors have limited success as single agents in ovarian cancer due to adaptive kinome reprogramming and therefore require combination therapies simultaneously targeting kinases and BET bromodomain proteins42. The gene discussed is DNER; the disease is ovarian cancer.